Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitafloxacin-Containing Regimens for Shortening Tuberculosis Treatment
ChiCTR2200060922Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sitafloxacin in pulmonary tuberculosis (TB) (4 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Outcome of treatment and Adverse events. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
sitafloxacin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2200060922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060922.